natgillin/translations-raw huggingface dataset:
Therefore, the CHMP’s view was that, as for Aclasta, the benefit outweighs the identified risk.
Zato je menil, da njegove koristi enako kot pri zdravilu Aclasta odtehtajo znana tveganja.
Therefore, the CHMP’s view was that, as for Aclasta, the benefit outweighs the identified risk.
Zato je menil, da njegove koristi, tako kot pri zdravilu Aclasta, odtehtajo znana tveganja.
Therefore, the CHMP’s view was that, as for Actos, the benefit outweighs the identified risk.
Zato je CHMP menil, da njegove koristi, tako kot pri zdravilu Actos, odtehtajo znana tveganja.
Therefore, the CHMP’s view was that, as for Actos, the benefit outweighs the identified risk.
Zato je menil, da njegove koristi, tako kot pri zdravilu Actos, odtehtajo znana tveganja.
Therefore, the CHMP’s view was that, as for Actos, the benefits outweigh the identified risks.
Zato je menil, da njegove koristi, tako kot pri zdravilu Actos, odtehtajo znana tveganja.
Therefore, the CHMP’s view was that, as for Aerius, the benefit outweighs the identified risk.
Zato je CHMP menil, da njegove koristi, tako kot pri zdravilu Aerius, odtehtajo znana tveganja.
Therefore, the CHMP’s view was that, as for Alimta, the benefit outweighs the identified risk.
Zato je menil, da njegove koristi enako kot pri zdravilu Alimta odtehtajo znana tveganja.
Therefore, the CHMP’s view was that, as for Aloxi, the benefit outweighs the identified risk.
Zato je menil, da njegove koristi enako kot pri zdravilu Aloxi odtehtajo znana tveganja.
Therefore, the CHMP’s view was that, as for Ammonaps, the benefit outweighs the identified risk.
Zato je menil, da njegove koristi, tako kot pri zdravilu Ammonaps, odtehtajo znana tveganja.
Therefore, the CHMP’s view was that, as for Aprovel, the benefit outweighs the identified risk.
Zaradi tega je CHMP menil, da koristi, tako kot pri zdravilu Aprovel, odtehtajo znana tveganja.
Therefore, the CHMP’s view was that, as for Aprovel, the benefit outweighs the identified risk.
Zato je CHMP menil, da koristi, tako kot pri zdravilu Aprovel, odtehtajo znana tveganja.
Therefore, the CHMP’s view was that, as for Aprovel, the benefit outweighs the identified risk.
Zato je menil, da koristi, tako kot pri zdravilu Aprovel, odtehtajo znana tveganja.
Therefore, the CHMP’s view was that, as for Arava, the benefit outweighs the identified risk.
Zato je CHMP menil, da njegove koristi, tako kot pri zdravilu Arava, odtehtajo znana tveganja.
Therefore, the CHMP’s view was that, as for Arava, the benefit outweighs the identified risk.
Zato je menil, da njegove koristi tako kot pri zdravilu Arava odtehtajo znana tveganja.
Therefore, the CHMP’s view was that, as for Arava, the benefit outweighs the identified risk.
Zato je menil, da njegove koristi, tako kot pri zdravilu Arava, odtehtajo znana tveganja.
Therefore, the CHMP’s view was that, as for Axura, the benefit outweighs the identified risk.
Zato je menil, da njegove koristi tako kot pri zdravilu Axura odtehtajo znana tveganja.
Therefore, the CHMP’s view was that, as for Axura, the benefit outweighs the identified risk.
Zato je menil, da njegove koristi, tako kot pri zdravilu Axura, odtehtajo znana tveganja.
Therefore, the CHMP’s view was that, as for Azilect, the benefit outweighs the identified risk.
Zato je menil, da njegove koristi enako kot pri zdravilu Azilect odtehtajo znana tveganja.
Therefore, the CHMP’s view was that, as for Bondronat and Bonviva, the benefit outweighs the identified risk.
Zato je menil, da njegove koristi, tako kot pri zdravilih Bondronat in Bonviva, odtehtajo znana tveganja.
Therefore, the CHMP’s view was that, as for Bondronat, the benefit outweighs the identified risk.
Zaradi tega je CHMP menil, da njegove koristi tako kot pri zdravilu Bondronat odtehtajo z njim povezana tveganja.
Therefore, the CHMP’s view was that, as for Bondronat, the benefit outweighs the identified risk.
Zato je menil, da njegove koristi tako kot pri zdravilu Bondronat odtehtajo z njim povezana tveganja.
Therefore, the CHMP’s view was that, as for Busilvex, the benefit outweighs the identified risk.
Zato je menil, da njegove koristi enako kot pri zdravilu Busilvex odtehtajo znana tveganja.
Therefore, the CHMP’s view was that, as for Cancidas, the benefit outweighs the identified risk.
Zato je menil, da njegove koristi enako kot pri zdravilu Cancidas odtehtajo znana tveganja.
Therefore, the CHMP’s view was that, as for Cellcept, the benefit outweighs the identified risk.
Zato je CHMP menil, da so koristi zdravila Myclausen, tako kot pri zdravilu CellCept, večje od znanih tveganj.
Therefore, the CHMP’s view was that, as for CellCept, the benefit outweighs the identified risk.
Zato je menil, da so njegove koristi, tako kot pri zdravilu CellCept, večje od znanih tveganj.
Therefore, the CHMP’s view was that, as for Cialis, the benefit outweighs the identified risk.
Zato je menil, da njegove koristi enako kot pri zdravilu Cialis odtehtajo znana tveganja.
Therefore, the CHMP’s view was that, as for CoAprovel, the benefit outweighs the identified risk.
Zato je menil, da koristi zdravila Ifirmacombi, tako kot pri zdravilu CoAprovel, odtehtajo znana tveganja.
Therefore, the CHMP’s view was that, as for CoAprovel, the benefit outweighs the identified risk.
Zato je menil, da koristi, tako kot pri zdravilu CoAprovel, odtehtajo znana tveganja.
Therefore, the CHMP’s view was that, as for Combivir, the benefit outweighs the identified risk.
Zato je menil, da njegove koristi enako kot pri zdravilu Combivir odtehtajo znana tveganja.
Therefore, the CHMP’s view was that, as for Comtess, the benefit outweighs the identified risk.
Zato je menil, da njegove koristi enako kot pri zdravilu Comtess, odtehtajo znana tveganja.
Therefore, the CHMP’s view was that, as for Cymbalta, the benefit outweighs the identified risk.
Zato je menil, da njegove koristi enako kot pri zdravilu Cymbalta odtehtajo znana tveganja.
Therefore, the CHMP’s view was that, as for Ebixa, the benefit outweighs the identified risk.
Zato je menil, da njegove koristi, tako kot pri zdravilu Ebixa, odtehtajo znana tveganja.
Therefore, the CHMP’s view was that, as for Enbrel, the benefit outweighs the identified risk.
Zato je menil, da njegove koristi enako kot pri zdravilu Enbrel odtehtajo znana tveganja.
Therefore, the CHMP’s view was that, as for Epivir, the benefit outweighs the identified risk.
Zato je menil, da njegove koristi enako kot pri zdravilu Epivir odtehtajo znana tveganja.
Therefore, the CHMP’s view was that, as for Eprex/Erypo, the benefit outweighs the identified risks.
Zato je menil, da njegove koristi enako kot pri zdravilu Eprex/Erypo odtehtajo znana tveganja.
Therefore, the CHMP’s view was that, as for Eprex/Erypo, the benefit outweighs the identified risks.
Zato je menil, da njegove koristi, tako kot pri zdravilu Eprex/Erypo, odtehtajo znana tveganja.
Therefore, the CHMP’s view was that, as for Evista, the benefit outweighs the identified risk.
Zato je menil, da njegove koristi, tako kot pri zdravilu Evista, odtehtajo znana tveganja.
Therefore, the CHMP’s view was that, as for Exelon, the benefit outweighs the identified risk.
Zato je CHMP menil, da koristi zdravila Nimvastid, tako kot pri zdravilu Exelon, odtehtajo znana tveganja.
Therefore, the CHMP’s view was that, as for Exelon, the benefit outweighs the identified risk.
Zato je CHMP menil, da koristi zdravila Rivastigmine Teva, tako kot pri zdravilu Exelon, odtehtajo znana tveganja.
Therefore, the CHMP’s view was that, as for Exelon, the benefit outweighs the identified risk.
Zato je menil, da koristi zdravila Rivastigmine Actavis, tako kot pri zdravilu Exelon, odtehtajo znana tveganja.
Therefore, the CHMP’s view was that, as for Exelon, the benefit outweighs the identified risk.
Zato je menil, da njegove koristi enako kot pri zdravilu Exelon odtehtajo znana tveganja.
Therefore, the CHMP’s view was that, as for Exforge, the benefit outweighs the identified risk.
Zato je menil, da njegove koristi enako kot pri zdravilu Exforge odtehtajo znana tveganja.
Therefore, the CHMP’s view was that, as for Genotropin, the benefit outweighs the identified risk.
Zato je CHMP sklenil, da so njegove koristi, podobno kot pri zdravilu Genotropin, večje od z njim povezanih znanih tveganj.
Therefore, the CHMP’s view was that, as for Glivec, the benefit outweighs the identified risk.
Zato je menil, da njegove koristi enako kot pri zdravilu Glivec odtehtajo znana tveganja.
Therefore, the CHMP’s view was that, as for Glivec, the benefit outweighs the identified risk.
Zato je menil, da njegove koristi, tako kot pri zdravilu Glivec, odtehtajo znana tveganja.
Therefore, the CHMP’s view was that, as for GONAL-f, Ovaleap’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Zato je menil, da so koristi zdravila Ovaleap tako kot pri zdravilu GONAL-f večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
Therefore, the CHMP’s view was that, as for GONAL-f, the benefits of Bemfola outweigh the identified risks.
Zato je menil, da njegove koristi enako kot pri zdravilu GONAL-f odtehtajo znana tveganja.
Therefore, the CHMP’s view was that, as for Humatrope, the benefit outweighs the identified risks.
Zaradi tega je CHMP menil, da so koristi zdravila Valtropin, tako kot pri zdravilu Humatrope, večje od z njim povezanih tveganj.
Therefore, the CHMP’s view was that, as for Hycamtin, the benefit outweighs the identified risk.
Zato je CHMP menil, da njegove koristi, tako kot pri zdravilu Hycamtin, odtehtajo znana tveganja.
Therefore, the CHMP’s view was that, as for Hycamtin, the benefit outweighs the identified risk.
Zato je menil, da njegove koristi, tako kot pri zdravilu Hycamtin, odtehtajo znana tveganja.
Therefore, the CHMP’s view was that, as for Integrilin, the benefit outweighs the identified risk.
Zato je menil, da njegove koristi enako kot pri zdravilu Integrilin, odtehtajo znana tveganja.
Therefore, the CHMP’s view was that, as for Kaletra, the benefit outweighs the identified risk.
Zato je menil, da njegove koristi enako kot pri zdravilu Kaletra odtehtajo znana tveganja.
Therefore, the CHMP’s view was that, as for Keppra, the benefit outweighs the identified risk.
Zato je CHMP menil, da njegove koristi, tako kot pri zdravilu Keppra, odtehtajo znana tveganja.
Therefore, the CHMP’s view was that, as for Keppra, the benefit outweighs the identified risk.
Zato je menil, da njegove koristi enako kot pri zdravilu Keppra odtehtajo znana tveganja.
Therefore, the CHMP’s view was that, as for Lantus, the benefit outweighs the identified risk.
Zato je menil, da njegove koristi enako kot pri zdravilu Lantus odtehtajo znana tveganja.
Therefore, the CHMP’s view was that, as for Lyrica, the benefit outweighs the identified risk.
Zato je menil, da njegove koristi enako kot pri zdravilu Lyrica odtehtajo znana tveganja.
Therefore, the CHMP’s view was that, as for Micardis, the benefit outweighs the identified risk.
Zato je CHMP menil, da njegove koristi, tako kot pri zdravilu Micardis, odtehtajo znana tveganja.
Therefore, the CHMP’s view was that, as for Micardis, the benefit outweighs the identified risk.
Zato je menil, da njegove koristi, tako kot pri zdravilu Micardis, odtehtajo znana tveganja.
Therefore, the CHMP’s view was that, as for MicardisPlus, the benefit outweighs the identified risk.
Zato je menil, da njegove koristi, tako kot pri zdravilu MicardisPlus, odtehtajo znana tveganja.
Therefore, the CHMP’s view was that, as for Mimpara, the benefit outweighs the identified risk.
Zato je menil, da njegove koristi enako kot pri zdravilu Mimpara odtehtajo znana tveganja.
Therefore, the CHMP’s view was that, as for Mirapexin, the benefit outweighs the identified risk.
Zato je menil, da njegove koristi enako kot pri zdravilu Mirapexin, odtehtajo znana tveganja.
Therefore, the CHMP’s view was that, as for Neupogen, the benefit outweighs the identified risk.
Zaradi tega je CHMP menil, da so koristi zdravila Biograstim, tako kot pri zdravilu Neupogen, večje od znanih tveganj.
Therefore, the CHMP’s view was that, as for Neupogen, the benefit outweighs the identified risk.
Zaradi tega je CHMP menil, da so koristi zdravila Filgrastim ratiopharm, tako kot pri zdravilu Neupogen, večje od znanih tveganj.
Therefore, the CHMP’s view was that, as for Neupogen, the benefit outweighs the identified risk.
Zaradi tega je CHMP menil, da so koristi zdravila Tevagrastim, tako kot pri zdravilu Neupogen, večje od znanih tveganj.
Therefore, the CHMP’s view was that, as for Neupogen, the benefit outweighs the identified risk.
Zaradi tega je menil, da so koristi, tako kot pri zdravilu Neupogen, večje od z njim povezanih tveganj.
Therefore, the CHMP’s view was that, as for Neupogen, the benefit outweighs the identified risk.
Zato je CHMP menil, da so njegove koristi, kot pri zdravilu Neupogen, večje od z njim povezanih tveganj.
Therefore, the CHMP’s view was that, as for Neupogen, the benefit outweighs the identified risks and recommended that it be approved for use in the EU.
Zato je menil, da so njegove koristi, tako kot pri zdravilu Neupogen, večje od znanih tveganj, in priporočil, da se odobri za uporabo v EU.
Therefore, the CHMP’s view was that, as for Neupogen, the benefit outweighs the identified risks.
Zato je menil, da njegove koristi enako kot pri zdravilu Neupogen odtehtajo znana tveganja.
Therefore, the CHMP’s view was that, as for NovoNorm, the benefit outweighs the identified risk.
Zato je CHMP menil, da njegove koristi, tako kot pri zdravilu NovoNorm, odtehtajo znana tveganja.
Therefore, the CHMP’s view was that, as for other authorised forms of tacrolimus, the benefit outweighs the identified risk.
Zato je menil, da koristi enako kot pri ostalih odobrenih oblikah takrolimusa odtehtajo znana tveganja.
Therefore, the CHMP’s view was that, as for Plavix, the benefit outweighs the identified risk.
Zato je CHMP menil, da njegove koristi, tako kot pri zdravilu Plavix, odtehtajo znana tveganja.
Therefore, the CHMP’s view was that, as for Plavix, the benefit outweighs the identified risk.
Zato je menil, da njegove koristi enako kot pri zdravilu Plavix odtehtajo znana tveganja.
Therefore, the CHMP’s view was that, as for Plavix, the benefit outweighs the identified risk.
Zato je menil, da njegove koristi, tako kot pri zdravilu Plavix, odtehtajo znana tveganja.
Therefore, the CHMP’s view was that, as for Rebetol, the benefit outweighs the identified risk.
Zato je CHMP menil, da njegove koristi, tako kot pri zdravilu Rebetol, odtehtajo znana tveganja.
Therefore, the CHMP’s view was that, as for reference medicine, the benefits of Nordimet outweighs it risks.
Zato je menil, da njegove koristi enako kot pri referenčnem zdravilu odtehtajo tveganja.
Therefore, the CHMP’s view was that, as for Remicade, the benefit outweighs the identified risk.
Zato je menil, da njegove koristi enako kot pri zdravilu Remicade odtehtajo znana tveganja.
Therefore, the CHMP’s view was that, as for Remicade, the benefit outweighs the identified risks.
Zato je menil, da so njegove koristi, tako kot pri zdravilu Remicade, večje od znanih tveganj.
Therefore, the CHMP’s view was that, as for Seretide Diskus, the benefit outweighs the identified risk.
Zato je menil, da njegove koristi enako kot pri zdravilu Seretide Diskus odtehtajo znana tveganja.
Therefore, the CHMP’s view was that, as for Sifrol, the benefit outweighs the identified risk.
Zaradi tega je CHMP menil, da njegove koristi tako kot pri zdravilu Sifrol odtehtajo z njim povezana tveganja.
Therefore, the CHMP’s view was that, as for Sifrol, the benefit outweighs the identified risk.
Zaradi tega je menil, da njegove koristi tako kot pri zdravilu Sifrol odtehtajo z njim povezana tveganja.
Therefore, the CHMP’s view was that, as for Sustiva, the benefit outweighs the identified risk.
Zato je CHMP menil, da njegove koristi, tako kot pri zdravilu Sustiva, odtehtajo znana tveganja.
Therefore, the CHMP’s view was that, as for Symbicort Turbohaler, the benefit outweighs the identified risk.
Zato je menil, da njegove koristi enako kot pri zdravilu Symbicort Turbohaler odtehtajo znana tveganja.
Therefore, the CHMP’s view was that, as for Tamiflu, the benefit outweighs the identified risks.
Zato je menil, da njegove koristi, tako kot pri zdravilu Tamiflu, odtehtajo znana tveganja.
Therefore, the CHMP’s view was that, as for Taxotere, the benefit outweighs the identified risk.
Zato je CHMP menil, da koristi zdravila Taxotere odtehtajo znana tveganja.
Therefore, the CHMP’s view was that, as for Taxotere, the benefit outweighs the identified risk.
Zato je CHMP menil, da njegove koristi, tako kot pri zdravilu Taxotere, odtehtajo znana tveganja.
Therefore, the CHMP’s view was that, as for Taxotere, the benefit outweighs the identified risk.
Zato je menil, da njegove koristi, tako kot pri zdravilu Taxotere, odtehtajo znana tveganja.
Therefore, the CHMP’s view was that, as for Temodal, the benefit outweighs the identified risk.
Zato je CHMP menil, da tako kot pri zdravilu Temodal koristi odtehtajo znana tveganja.
Therefore, the CHMP’s view was that, as for Temodal, the benefit outweighs the identified risk.
Zato je menil, da tako kot pri zdravilu Temodal koristi odtehtajo znana tveganja.
Therefore, the CHMP’s view was that, as for Tractocile, the benefit outweighs the identified risk.
Zato je menil, da njegove koristi, tako kot pri zdravilu Tractocile, odtehtajo znana tveganja.
Therefore, the CHMP’s view was that, as for Velcade, the benefit outweighs the identified risk.
Zato je menil, da njegove koristi enako kot pri zdravilu Velcade odtehtajo znana tveganja.
Therefore, the CHMP’s view was that, as for Vfend, the benefit outweighs the identified risk.
Zato je menil, da njegove koristi enako kot pri zdravilu Vfend odtehtajo znana tveganja.
Therefore, the CHMP’s view was that, as for Vfend, the benefit outweighs the identified risks.
Zato je menil, da njegove koristi enako kot pri zdravilu Vfend odtehtajo znana tveganja.
Therefore, the CHMP’s view was that, as for Viagra, the benefit outweighs the identified risk.
Zato je menil, da koristi zdravila tako kot pri zdravilu Viagra odtehtajo znana tveganja.
Therefore, the CHMP’s view was that, as for Viagra, the benefit outweighs the identified risk.
Zato je menil, da koristi zdravila, tako kot pri zdravilu Viagra, odtehtajo znana tveganja.
Therefore, the CHMP’s view was that, as for Viagra, the benefit outweighs the identified risk.
Zato je menil, da njegove koristi, tako kot pri zdravilu Viagra, odtehtajo znana tveganja.
Therefore, the CHMP’s view was that, as for Viramune, the benefit outweighs the identified risk.
Zato je menil, da njegove koristi, tako kot pri zdravilu Viramune, odtehtajo znana tveganja.
Therefore, the CHMP’s view was that, as for Xeloda, the benefit outweighs the identified risk.
Zato je CHMP menil, da njegove koristi, tako kot pri zdravilu Xeloda, odtehtajo znana tveganja.
Therefore, the CHMP’s view was that, as for Xeloda, the benefit outweighs the identified risk.
Zato je menil, da njegove koristi, tako kot pri zdravilu Xeloda, odtehtajo znana tveganja.
Therefore, the CHMP’s view was that, as for Zeffix, the benefit outweighs the identified risk.
Zato je CHMP menil, da njegove koristi, tako kot pri zdravilu Zeffix, odtehtajo znana tveganja.
Therefore, the CHMP’s view was that, as for Zometa and Aclasta, the benefit outweighs the identified risks.
Zato je menil, da njegove koristi tako kot pri zdravilih Zometa in Aclasta odtehtajo znana tveganja.
Therefore, the CHMP’s view was that, as for Zometa, the benefit outweighs the identified risk.
Zato je menil, da njegove koristi enako kot pri zdravilu Zometa odtehtajo znana tveganja.
Therefore, the CHMP’s view was that, as for Zometa, the benefit outweighs the identified risk.
Zato je menil, da njegove koristi tako kot pri zdravilu Zometa odtehtajo znana tveganja.
Therefore, the CHMP’s view was that, as for Zometa, the benefit outweighs the identified risk.
Zato je menil, da njegove koristi, tako kot pri zdravilu Zometa, odtehtajo znana tveganja.
Therefore, the CHMP’s view was that, as for Zonegran, the benefit outweighs the identified risk.
Zato je menil, da njegove koristi enako kot pri zdravilu Zonegran odtehtajo znana tveganja.
Therefore, the CHMP’s view was that, as for Zyprexa and Zyprexa Velotab, the benefit outweighs the identified risk.
CHMP je zato mnenja, da so koristi, tako kot pri zdravilih Zyprexa in Zyprexa Velotab, večje od z njim povezanih tveganj.
Therefore, the CHMP’s view was that, as for Zyprexa and Zyprexa Velotab, the benefit outweighs the identified risk.
Zaradi tega je CHMP menil, da koristi zdravila Zalasta tako kot pri zdravilih Zyprexa in Zyprexa Velotab odtehtajo znana tveganja.
Therefore, the CHMP’s view was that, as for Zyprexa and Zyprexa Velotab, the benefit outweighs the identified risk.
Zato meni, da so koristi, tako kot pri zdravilih Zyprexa in Zyprexa Velotab, večje od z njim povezanih tveganj.
Therefore, the CHMP’s view was that, as for Zyprexa, the benefit outweighs the identified risk.
Zato je CHMP menil, da so koristi zdravila Olanzapine Mylan, tako kot pri zdravilu Zyprexa, večje od z njim povezanih tveganj.
Therefore, the CHMP’s view was that, as for Zyprexa, the benefit outweighs the identified risk.
Zato je menil, da koristi, tako kot pri zdravilu Zyprexa, odtehtajo znana tveganja.
Therefore, the combination of adalimumab and anakinra is not recommended. (See section 4.5).
Zato kombinacija adalimumaba in anakinre ni priporočena (glejte poglavje 4.5).
Therefore, the combination of adalimumab and anakinra is not recommended. (See section 4.5).
Zato kombinacija adalimumaba in anakinre ni priporočljiva (glejte poglavje 4.5).
Therefore, the combination of Inflectra and anakinra is not recommended.
Kombiniranje zdravila Inflectra in anakinre torej ni priporočljivo.
Therefore, the combination of Oncaspar with oral contraception is not recommended.
Zato kombinacija zdravila Oncaspar s peroralno kontracepcijo ni priporočljiva.
Therefore, the combination of Remsima and anakinra is not recommended.
Kombiniranje zdravila Remsima in anakinre torej ni priporočljivo.
Therefore, the combination should be administered with caution, especially in the elderly.
Zato je treba takšno kombinacijo, posebno pri starejših osebah, uporabljati zelo previdno.
Therefore, the Committee concluded that Atripla could be a convenient ‘one-tablet once-a-day’ treatment when used to maintain low viral loads in patients already taking HIV treatment, but there is not enough information to be certain about its effects in patients who have not been treated before.
Zato je zaključil, da bi zdravilo Atripla lahko bilo primerno kot zdravljenje v obliki „ena tableta enkrat na dan“, kadar se uporablja za vzdrževanje nizkega virusnega bremena pri bolnikih, ki se proti okužbi z virusom HIV že zdravijo, vendar pa ni dovolj zanesljivih podatkov o njegovi učinkovitosti pri bolnikih, ki zdravljenja še niso prejemali.
Therefore, the Committee concluded that MabCampath’s benefits are greater than its risks for the treatment of patients with B-CLL for whom fludarabine combination chemotherapy is not appropriate.
Odbor je zaključil, da so koristi zdravila MabCampath pri zdravljenju bolnikov z B-celično kronično limfocitno levkemijo, pri katerih s fludarabinom kombinirana kemoterapija ni bila primerna, večje od z njim povezanih tveganj.
Therefore, the Committee decided that Atriance’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Zato je zaključil, da so koristi zdravila večje od z njim povezanih tveganj, in priporočil, da se zanj izda dovoljenje za promet.
Therefore, the Committee decided that Exelon’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Odbor je zato menil, da so koristi zdravila Exelon večje od z njim povezanih tveganj, in priporočil, da se zanj odobri dovoljenje za promet.
Therefore, the Committee decided that HBVaxPro’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Zato je CHMP zaključil, da so koristi zdravila HBVaxPro večje od z njim povezanih tveganj, in priporočil, da se zanj odobri dovoljenje za promet.